Bicycle Therapeutics plc (BCYC) Ownership
BCYC ownership summary
as of October 18, 2026- Institutions
- 71.9% of shares outstanding
- Insiders
- 4.41% of shares outstanding
- Shares outstanding
- 50.4M
- Float
- 7.8M shares available to trade
- Short interest
- 8.46% 3.3M shares short
- Days to cover
- 7.64 short interest down 0.9% vs prior month
- Institutions 71.86%
- Insiders 4.41%
- Other investors 23.74%
BCYC top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Baker Bros Advisors LP | 15.55% | 10.9M | $37.7M | — | June 30, 2026 |
| 2 | FCPM III SERVICES BV | 4.96% | 3.5M | $12.0M | — | June 30, 2026 |
| 3 | Armistice Capital, LLC | 4.85% | 3.4M | $11.8M | — | June 30, 2026 |
| 4 | Long Focus Capital Management, LLC | 4.73% | 3.3M | $11.5M | — | June 30, 2026 |
| 5 | Acadian Asset Management LLC | 2.81% | 2.0M | $6.8M | — | June 30, 2026 |
| 6 | Renaissance Technologies Corp | 2.19% | 1.5M | $5.3M | +554,100 (+56.6%) | June 30, 2026 |
| 7 | GSK PLC | 2.19% | 1.5M | $5.3M | — | June 30, 2026 |
| 8 | T. Rowe Price Associates, Inc. | 1.29% | 902K | $3.1M | −126,093 (−12.3%) | June 30, 2026 |
| 9 | Marshall Wace Asset Management Ltd | 1.14% | 798K | $2.8M | +420,605 (+111.5%) | June 30, 2026 |
| 10 | Qube Research & Technologies | 1.11% | 776K | $2.7M | +466,950 (+151.3%) | June 30, 2026 |
| 11 | Morgan Stanley - Brokerage Accounts | 0.95% | 667K | $2.3M | +48,942 (+7.9%) | June 30, 2026 |
| 12 | Schroder Investment Management Group | 0.88% | 616K | $2.1M | — | June 30, 2026 |
| 13 | Citadel Advisors Llc | 0.79% | 554K | $1.9M | +177,140 (+47.0%) | June 30, 2026 |
| 14 | Millennium Management LLC | 0.79% | 554K | $1.9M | +269,981 (+95.1%) | June 30, 2026 |
| 15 | Peapod Lane Capital LLC | 0.77% | 538K | $1.9M | +416,872 (+344.2%) | June 30, 2026 |
| 16 | Diadema Partners LP | 0.66% | 463K | $1.6M | −13,700 (−2.9%) | June 30, 2026 |
| 17 | Two Sigma Investments LLC | 0.62% | 435K | $1.5M | +269,777 (+163.7%) | June 30, 2026 |
| 18 | Jane Street Group LLC | 0.56% | 392K | $1.4M | +174,048 (+79.8%) | June 30, 2026 |
| 19 | FLAX POND CAPITAL, LLC | 0.54% | 376K | $1.3M | +200,086 (+113.6%) | June 30, 2026 |
| 20 | Birchview Capital, LP | 0.45% | 314K | $1.1M | −149,983 (−32.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 3.0M shares and 3 cut 290K.
BCYC top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | International Biotechnology Ord | 0.88% | 616K | $2.1M | — | June 30, 2026 |
| 2 | iShares Biotechnology ETF | 0.42% | 292K | $1.0M | −2,208 (−0.8%) | September 30, 2026 |
| 3 | Old Westbury Small & Mid Cap Strategies | 0.38% | 266K | $920,267 | — | July 31, 2026 |
| 4 | Virtus LifeSci Biotech Clinical Trls ETF | 0.11% | 78K | $271,105 | — | September 30, 2026 |
| 5 | ALPS Medical Breakthroughs ETF | 0.10% | 67K | $230,093 | — | September 30, 2026 |
| 6 | PPF Helix Biotechnology I USD | 0.08% | 58K | $201,718 | — | June 30, 2026 |
| 7 | TD Health Sciences - I | 0.07% | 46K | $159,146 | — | June 30, 2026 |
| 8 | iShares Nasdaq US Biotech ETF USD Acc | 0.05% | 38K | $131,518 | +328 (+0.9%) | September 30, 2026 |
| 9 | State Street® SPDR® S&P® Intl Sm Cp ETF | 0.05% | 37K | $128,798 | — | September 30, 2026 |
| 10 | Voya Multi-Manager International Sm Cp A | 0.04% | 30K | $103,980 | — | June 30, 2026 |
| 11 | Invesco NASDAQ Future Gen 200 ETF | 0.04% | 29K | $100,420 | — | September 30, 2026 |
| 12 | Acadian Eurp Eq C2-i-0.7500-EUR | 0.04% | 26K | $89,856 | — | June 30, 2026 |
| 13 | JHVIT Health Sciences I | 0.04% | 26K | $88,583 | — | August 31, 2026 |
| 14 | Acadian European SmCp Eq C2-i-0.7500-EUR | 0.03% | 24K | $83,383 | — | June 30, 2026 |
| 15 | ActivePassive International Equity ETF | 0.03% | 20K | $70,719 | — | September 30, 2026 |
| 16 | Portland Life Sciences Alt F | 0.02% | 15K | $51,900 | — | September 30, 2026 |
| 17 | ERSTE STOCK BIOTEC EUR R01 A | 0.02% | 14K | $48,440 | — | August 31, 2026 |
| 18 | The AtonRâ Fund Founder USD Acc | 0.02% | 12K | $40,122 | −3,111 (−21.2%) | June 30, 2026 |
| 19 | Horizon Kinetics Medical ETF | 0.02% | 11K | $39,354 | — | September 30, 2026 |
| 20 | Steward Values Enhanced International I | 0.02% | 11K | $38,783 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BCYC insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Kevin Lee | Sell | $5.05 | 1,716 | $8,666 |
| 2026-04-06 | Travis Alvin Thompson | Sell | $5.05 | 102 | $515 |
| 2026-04-06 | Jennifer Scott Perry | Sell | $5.04 | 370 | $1,865 |
| 2026-04-02 | Jennifer Scott Perry | Sell | $4.91 | 1,038 | $5,097 |
| 2026-04-02 | Kevin Lee | Sell | $4.91 | 5,967 | $29,298 |
| 2026-04-02 | Travis Alvin Thompson | Sell | $4.91 | 799 | $3,923 |
| 2026-01-05 | Alethia Young | Sell | $6.49 | 4,334 | $28,128 |
| 2026-01-05 | Alistair Milnes | Sell | $6.46 | 3,416 | $22,067 |
| 2026-01-05 | Kevin Lee | Sell | $6.46 | 10,989 | $70,989 |
| 2026-01-05 | Travis Alvin Thompson | Sell | $6.45 | 1,115 | $7,192 |
| 2026-01-02 | Alethia Young | Sell | $6.80 | 3,289 | $22,365 |
| 2026-01-02 | Alistair Milnes | Sell | $6.80 | 3,244 | $22,059 |
| 2026-01-02 | Kevin Lee | Sell | $6.80 | 10,325 | $70,210 |
| 2026-01-02 | Travis Alvin Thompson | Sell | $6.80 | 1,317 | $8,956 |
| 2025-10-03 | Alistair Milnes | Sell | $8.41 | 978 | $8,225 |
| 2025-10-03 | Travis Alvin Thompson | Sell | $8.41 | 103 | $866 |
| 2025-10-03 | Kevin Lee | Sell | $8.41 | 3,231 | $27,173 |
| 2025-10-02 | Alethia Young | Sell | $8.51 | 482 | $4,102 |
| 2025-10-02 | Alistair Milnes | Sell | $8.40 | 1,147 | $9,635 |
| 2025-10-02 | Kevin Lee | Sell | $8.40 | 2,263 | $19,009 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BCYC shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BCYC
Institutional investors own 71.9% of Bicycle Therapeutics's shares and insiders 4.41%. The largest holder is Baker Bros Advisors LP with 15.55% of the shares (10.9M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 3 reduced their stake in the latest filings. Short interest is 8.46% of the float, or 7.64 days of average trading volume. The share count rose 347.7% since 2017.
Related: BCYC analyst forecast, BCYC key metrics. See the BCYC stock overview for the latest quote and news.
BCYC ownership FAQ
Who owns the most Bicycle Therapeutics stock?
The largest shareholders of Bicycle Therapeutics are Baker Bros Advisors LP (15.55%), FCPM III SERVICES BV (4.96%), Armistice Capital, LLC (4.85%), Long Focus Capital Management, LLC (4.73%), Acadian Asset Management LLC (2.81%).
What percentage of Bicycle Therapeutics is owned by institutions?
Institutions hold 71.9% of Bicycle Therapeutics's shares outstanding; insiders hold 4.41%.
Which funds own Bicycle Therapeutics?
The largest fund holders of Bicycle Therapeutics are International Biotechnology Ord (0.88%), iShares Biotechnology ETF (0.42%), Old Westbury Small & Mid Cap Strategies (0.38%), Virtus LifeSci Biotech Clinical Trls ETF (0.11%), ALPS Medical Breakthroughs ETF (0.10%).
What is Bicycle Therapeutics's short interest?
3.3M shares of Bicycle Therapeutics were sold short, 8.46% of the float; at the average daily volume it would take 7.64 days to cover.
Are insiders buying or selling Bicycle Therapeutics?
Of the latest 20 reported insider transactions in Bicycle Therapeutics (since October 2, 2025), 0 were purchases and 20 were sales.
How many shares of Bicycle Therapeutics are outstanding?
Bicycle Therapeutics has 50.4M shares outstanding, of which 7.8M are in the public float.